Avtar Singh Gautam

About

I am Avtar Singh Gautam, a Ph.D. scholar in the Department of Pharmacology and Toxicology at NIPER Raebareli. I hold a master’s degree in Pharmacology and Toxicology from NIPER Hajipur, where I developed a strong foundation in pharmacological research. During my master’s dissertation at CSIR-Central Drug Research Institute, Lucknow, I gained hands-on experience in animal experimentation and histological techniques. Currently, my doctoral research focuses on neuroimmunology, specifically identifying IL-17 as a therapeutic target in Alzheimer’s disease. I have presented my work at international platforms, including the EMBO Workshop on Neuropeptides and Behavioural Flexibility, where I had the opportunity to connect with researchers from around the world.

Employment

Employment history is unavailable.

Education

• National Institute of Pharmaceutical Education and Research Hajipur M.S (Pharm.)
  2018 - 2020

Projects & Funding

Projects & funding information is unavailable.

Publications (17)

• Therapeutic potential of chrysin in regulation of interleukin-17 signaling in a repeated intranasal amyloid-beta-induced Alzheimer's disease model.
  Food & function 2025 DOI: 10.1039/d4fo05278a
  +Save
• Lipids and carotenoids may influence the neuropathology of Alzheimer's disease: A meta-analysis
  Archives of Gerontology and Geriatrics Plus 2024 DOI: 10.1016/j.aggp.2024.100072
  +Save
• IL-17A-Induced Redox Imbalance and Inflammatory Responses in Mice Lung via Act1-TRAF6-IKBα Signaling Pathway: Implications for Lung Disease Pathogenesis.
  Inflammation 2024 DOI: 10.1007/s10753-024-02199-9
  +Save
• MK2 inhibitor PF‐3644022 shows protective effect in mouse microglial N9 cell line induced with cigarette smoke extract
  Chemical Biology & Drug Design 2024 DOI: 10.1111/cbdd.14592
  +Save
• The role of RIPK1 in chronic obstructive pulmonary disease
  Drug Discovery Today 2024 DOI: 10.1016/j.drudis.2024.104020
  +Save
• Quercetin ameliorates neuroinflammatory and neurodegenerative biomarkers in brain and improves neurobehavioral parameters in repeated intranasal amyloid-beta exposed model of Alzheimer’s disease
  Food & Function 2024 DOI: 10.1039/d4fo02602k
  +Save
• Monoclonal antibodies for the management of central nervous system diseases: clinical success and future strategies.
  Expert opinion on biological therapy 2023 DOI: 10.1080/14712598.2023.2227378
  +Save
• Receptor tyrosine kinases
  Receptor Tyrosine Kinases in Neurodegenerative and Psychiatric Disorders 2023 DOI: 10.1016/b978-0-443-18677-6.00011-7
  +Save
• Neuroprotective responses of quercetin in regulation of biochemical, structural, and neurobehavioral effects in 28-day oral exposure of iron in rats
  Toxicology Mechanisms and Methods 2023 DOI: 10.1080/15376516.2023.2256840
  +Save
• Molecular and functional characteristics of receptor-interacting protein kinase 1 (RIPK1) and its therapeutic potential in Alzheimer's disease
  Drug Discovery Today 2023 DOI: 10.1016/j.drudis.2023.103750
  +Save